Navocaftor

DB19039InvestigationalSmall molecule

Navocaftor is under investigation in clinical trial NCT04853368 (Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/navocaftor/abbv-119 or Galicaftor/navocaftor/abbv-576 Combination Therapies in Adult Participants...

Mechanism: Pharmacologically active on Cystic fibrosis transmembrane conductance regulator
Curator reviewed
Formula / weight: C₁₅H₁₁F₃N₄O₅S · 416.33 g/mol (avg)
Also known as: (5-(3-amino-5-((4-(trifluoromethoxy)phenyl)sulfonyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanol · 1,3,4-oxadiazole-2-methanol, 5-(3-amino-5-((4-(trifluoromethoxy)phenyl)sulfonyl)-2-pyridinyl)-
Code names: ABBV-3067 · GLPG-3067

Resolves to

Compound

UNIIW2F2XU189OCAS2159103-66-7ChEMBLCHEMBL4802150

Structure

InChIKeyWOXOLLSAICIZNO-UHFFFAOYSA-NSMILESNC1=CC(=CN=C1C1=NN=C(CO)O1)S(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1

Targets

P13569CFTR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Navocaftor, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account